Therapy Areas: Oncology
Merz Expands in Dessau BioPharmaPark
16 September 2019 - - German aesthetics and neurotoxins specialist Merz has opened its new filler plant in BioPharmaPark, Dessau-Rosslau, Germany, the company said.

At the same time, Oncotec, a contract manufacturer subsidiary, celebrates 22 years of essential pharmaceutical production in Dessau, as well as a new USD 35m investment at its site in the BioPharmaPark.

Merz constructed the new plant to meet the growing global demand for its Belotero dermal fillers, expanding the range of products manufactured at its Dessau site.

The new building represents a EUR 15m investment and spans over 1.200 square meters on three floors. About 150 Merz employees are currently working at the company's Dessau site.

Oncotec, a global manufacturer of essential medicines in cancer and autoimmune diseases, specializes in particular in the production and development as well as the freeze-drying of liquid cytostatics.

Today, for the first time, Oncotec publicly unveils its robot-controlled filling line and installation for the fully automatic visual inspection of syringes to coincide with the company's 22nd anniversary of the successful production of medicinal products in Dessau-Rosslau.

The new production plant has been built to produce hyaluronic acid dermal fillers from the company's Beloteroproduct range. The production takes place according to the highest international standards under clean room conditions.

The expansion of the Dessau site enables Merz to increase overall production capacity to meet the growing demand for its HA dermal filler range, which is sold under the brand name Belotero.

In 2002, Merz established its initial production footprint in the BioPharmaPark in Dessau to manufacture the active pharmaceutical ingredient botulinum neurotoxin.

Merz soon invested in an aseptic plant at the Dessau site for the production of its own botulinum neurotoxin, used for the treatment of neurological movement disorders and medical aesthetics.

The company produces the active ingredient in a complex biotechnological process using aseptic filling and freeze-drying.

Merz is a global, family-owned aesthetics, specialty neurology and consumer care company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth.

In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4m; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries.

Oncotec Pharma Produktion GmbH has around 300 employees and specialises in the production and development of cytostatics and immunosuppressants in vials and pre filled syringes. Special freeze-dryers allow for the instant conservation of the filled liquids.

Founded in 1997, Oncotec as contract manufacturer guarantees the optimum technological prerequisites for the production of highly innovative, specialised products, for example through continuous investments and modernisation measures.

As a result, Oncotec is able to provide its international customers with the full service for the entire value chain of cytostatics manufacturing; from development and market launch to commercial production including visual inspection and analytics. Oncotec Pharma Produktion GmbH is a wholly owned subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH.
Login
Username:

Password: